Affiliation:
1. Oswaldo Cruz Foundation, Brazil
2. Oswaldo Cruz Foundation/FIOCRUZ, Brazil
3. FIOCRUZ, Brazil
Abstract
Medicines must comply with quality, safety, and efficacy pillars. Nowadays, organizations seek to incorporate new management models encouraged by quality program following the world trend regarding the technological revolution. The present research aims to improve the sterile pharmaceutical product batches release process, using the Failure Mode Effects Analysis (FMEA) method. This study addresses the gap in literature on quality risk management during batch release. The methodology uses a form adapted to the process in order to systematize the information, improving its comparison and analysis, thus estimating, the identification of potential failure modes and their effects on their performance. Made it possible to assign values for the severity, occurrence, and failure modes detection, to then determine the risk level and the priority of risk level. The results obtained showed the mitigation and elimination of failures in the process, as well as opportunities for improvement and causes of failures identification, improvement in the process performance indicators, greater reliability, and reduction in batch release time.
Keywords: good manufacturing practices pharmaceutical industry, risk management, risk management tools
Subject
Organic Chemistry,Biochemistry
Reference10 articles.
1. ABNT (2015). Brazilian association of technical standards. ABNT NBR ISO 9001- Quality Management Systems—Requirements. Rio de Janeiro.
2. ABNT (2009). Brazilian association of technical standards. ABNT NBR ISO 31.000: Risk Management - Principles and Guidelines. First edition. Rio de Janeiro.
3. Cagnin, F, Oliveira, M. C., & Assumpcao, M. R. P. (2015). Risk Management is part of the Quality Management System, XXXV National Meeting on Production Engineering. Global Perspectives for Production Engineering, Fortaleza, CE, Brazil.
4. Giorgetti, L. et al. (2020). View of the application of the FMEA tool for analysis of notifications of technical complaints of solid medicines in the context of Quality by Design. Brazilian Journal of Natural Sciences, 3(3), 474 -489.
5. Haraszkiewicz-Birkemeier, N., & Hołda, A. (2019). Current perspectives and challenges in the pharmaceutical, life science and healthcare sectors (July 26, 2019). SSRN. http://dx.doi.org/10.2139/ssrn.3427035